Ameen A Salahudeen
Overview
Explore the profile of Ameen A Salahudeen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1451
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lozachmeur A, Danek T, Yang Q, Rosasco M, Welch J, Go W, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):174.
PMID: 39103508
To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we developed and validated an assay that detects HLA LOH within the context of an FDA-approved...
2.
Salahudeen A, Seoane J, Yuki K, Mah A, Smith A, Kolahi K, et al.
Cell Rep
. 2023 Nov;
42(11):113355.
PMID: 37922313
Somatic copy number gains are pervasive across cancer types, yet their roles in oncogenesis are insufficiently evaluated. This inadequacy is partly due to copy gains spanning large chromosomal regions, obscuring...
3.
Seligson N, Kolesar J, Alam B, Baker L, Lamba J, Fridley B, et al.
Pharmacogenomics
. 2023 Sep;
24(13):731-738.
PMID: 37702060
Precision medicine has revolutionized clinical care for patients with cancer through the development of targeted therapy, identification of inherited cancer predisposition syndromes and the use of pharmacogenetics to optimize pharmacotherapy...
4.
Khaliq A, Erdogan C, Kurt Z, Turgut S, Grunvald M, Rand T, et al.
Genome Biol
. 2022 Jul;
23(1):156.
PMID: 35831907
No abstract available.
5.
Lau D, Khare S, Stein M, Jain P, Gao Y, BenTaieb A, et al.
Nat Commun
. 2022 Jul;
13(1):4053.
PMID: 35831288
The efficacy of immune checkpoint blockade (ICB) varies greatly among metastatic non-small cell lung cancer (NSCLC) patients. Loss of heterozygosity at the HLA-I locus (HLA-LOH) has been identified as an...
6.
Larsen B, Cancino A, Shaxted J, Salahudeen A
STAR Protoc
. 2022 May;
3(2):101407.
PMID: 35620075
High-content imaging of tumor organoids (TOs) treated with therapeutic agents provides detailed cell viability readouts at the organoid level. In contrast, most used protocols provide one number per well. While...
7.
Khaliq A, Erdogan C, Kurt Z, Turgut S, Grunvald M, Rand T, et al.
Genome Biol
. 2022 May;
23(1):113.
PMID: 35538548
Background: Colorectal cancer (CRC) consensus molecular subtypes (CMS) have different immunological, stromal cell, and clinicopathological characteristics. Single-cell characterization of CMS subtype tumor microenvironments is required to elucidate mechanisms of tumor...
8.
Ahmed T, Carty M, Wenric S, Dry J, Salahudeen A, Khan A, et al.
Brief Bioinform
. 2022 Apr;
23(3).
PMID: 35388408
Reproducibility of results obtained using ribonucleic acid (RNA) data across labs remains a major hurdle in cancer research. Often, molecular predictors trained on one dataset cannot be applied to another...
9.
Larsen B, Kannan M, Langer L, Leibowitz B, BenTaieb A, Cancino A, et al.
Cell Rep
. 2021 Jul;
36(4):109429.
PMID: 34320344
Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a...
10.
Vaidyanathan S, Baik R, Chen L, Bravo D, Suarez C, Abazari S, et al.
Mol Ther
. 2021 Apr;
30(1):223-237.
PMID: 33794364
Cystic fibrosis (CF) is a monogenic disease caused by impaired production and/or function of the CF transmembrane conductance regulator (CFTR) protein. Although we have previously shown correction of the most...